FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 24, 2002
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS.
DUSA Pharmaceuticals, Inc. ( "DUSA") issued a press release on May 24,
2002, attached to and made part of this report, announcing that a
DUSA(R)-supported British investigator study using Levulan(R) (aminolevulinic
acid HCl) photodynamic therapy (PDT) in a Phase I/II clinical trial for the
removal of High-Grade-Dysplasia (HGD) within areas of Barrett's Esophagus (BE)
reported positive results at the Digestive Disease Week (DDW) conference in San
Francisco; and further reporting encouraging preliminary interim results from
its company-sponsored Phase I/II Levulan PDT study for the treatment of HGD in
BE.
Except for historical information, this report and exhibit contain
certain forward-looking statements that involve known and unknown risk and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the continuing
follow-up of the enrolled patients, continuing support of the UK investigator
studies to optimize the therapy, expectations for clinical results from the
related DUSA study and beliefs regarding the role of the treatment in this
disease. Such risks and uncertainties include, but are not limited to the
results of clinical trials, reliance on third parties to manufacture Levulan (in
compliance with FDA regulations), the regulatory approval process, the
availability of funds to support the BE program, and other risks identified in
the Company's SEC filings from time to time.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
(c) Exhibits.
[99] Press Release dated May 24, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: May 24, 2002 By: /s/ D. Geoffrey Shulman
------------ ------------------------------
D. Geoffrey Shulman, MD, FRCPC
President, Chief Executive Officer